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Background: Hepatobiliary scintigraphy using 99mTc-mebrofenin has been used as an investigation to study liver
function after liver transplantation (LTx). Hepatic extraction fraction (HEF) is a measurement of the hepatic
extraction efficiency and hepatic extraction rate. With the purpose of evaluating a possible diverging effect of
cyclosporin A (CSA) and tacrolimus (TAC) on the HEF, we compared the HEF with biochemical and histological
parameters in LTx patients receiving either CSA or TAC.
Methods: Thirty-nine adult patients who underwent LTx due to hepatitis C virus (HCV) cirrhosis were evaluated. All
patients underwent a 3-month and 1-year follow-up that included hepatobiliary scintigraphy and biochemistry tests.
Liver biopsy was performed at 1 year. These clinical parameters were compared between the two groups, TAC
(n = 15) and CSA (n = 24).
Results: The average HEF was significantly lower in the CSA group compared to the TAC group both at 3 months
and 1 year after LTx. The liver biochemistry tests, average donor and recipient age, average cold ischemia time (CIT),
and a clearance were comparable in the two groups. The TAC group had more inflammation than the CSA group.
Moreover, three patients who converted from CSA to TAC increased their HEF values.
Conclusions: CSA-treated patients presented a lower HEF value on hepatobiliary scintigraphy in spite of
comparable liver function by traditional measurements indicating a decrease on HEF values by CSA.
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Hepatitis CBackground
Liver transplantation (LTx) is an established treatment
for patients with end-stage liver disease, and LTx has
been performed in Sweden since 1984 [1]. Liver cirrhosis
caused by hepatitis C virus (HCV) is a common indica-
tion for LTx [2]. Approximately one-fifth of transplant
recipients at our institute had liver cirrhosis caused by
HCV [3]. Recurrence of HCV infection can occur as
early as 4 weeks after liver transplantation [4]; this may* Correspondence: shinjiyamamoto2000@hotmail.com
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in any medium, provided the original work is pdevelop into severe hepatitis requiring anti-viral treat-
ment within the first 6 months after LTx [5-7]. The re-
currence of HCV infection is usually diagnosed by blood
biochemistry tests, HCV-RNA test, and liver graft bi-
opsy. Other methods are also used for follow-up and to
evaluate liver graft function after LTx. These include
radiological examinations, transient elastography (fibros-
can), and hepatobiliary scintigraphy. Hepatobiliary scin-
tigraphy has emerged as one of the valuable methods to
assess graft function [8-14]. The most common agent
used for nuclear imaging with scintigraphy worldwide
and by us is 99mTc-mebrofenin (2,4,6-trimethyl-3 bromo
iminodiacetic acid) [14-16]. Hepatobiliary scintigraphy isn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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operative structural complications such as biliary ob-
structions/dilatations and biliary leakage. In addition, it
can provide information concerning functional compo-
nents of the liver graft, such as the rate of uptake, per-
fusion, and excretion of a tracer [9]. One important
parameter of biliary scintigraphy that is of great value
in the evaluation of transplanted liver grafts is the hep-
atic extraction fraction (HEF) [14]. HEF is a measure-
ment of the hepatic extraction efficiency and hepatic
extraction rate [14-16]. We have previously reported a
significant correlation between early post-LTx HEF
values and biochemical parameters [14].
A high level of serum bilirubin in the blood is known to
interact with the uptake and/or excretion of scintigraphic
agents in the liver, thereby affecting the scintigraphy re-
sults [14]. A previous study performed in an animal model
showed that cyclosporin A (CSA) possibly impaired the
99mTc-mebrofenin excretion [17]. It might indicate that
CSA affects the rate of HEF negatively. However, this
negative effect has not been proved in scintigraphy with
humans so far. In this retrospective study, we analyzed the
results of hepatobiliary scintigraphy performed at the 3-
month and 1-year post-transplantation check-up in pa-
tients transplanted as a result of HCV cirrhosis. We then
compared the scintigraphic results to the traditional bio-
chemical and histological parameters between the two
groups of patients, receiving either CSA or tacrolimus
(TAC) with the purpose of evaluating a possible diverging
effect of these drugs on the HEF.
Methods
Patients
Thirty-nine adult patients who underwent LTx due to a
single indication, i.e., HCV cirrhosis at the Karolinska
University Hospital between March 2007 and May 2011,
were included in the study. During this time period, our
center performed routine hepatobiliary scintigraphy at 3
and 12 months after LTx. Thirty-eight patients received
a whole-liver graft (n = 38) and one received a right lobeTable 1 Characteristics of 39 HCV positive patients who unde
Total (n = 39)
Recipient age (years) (range, average ± S.D.) 42 to 67
56.1 ± 6.6
Gender (male/female) 25/14
HCC (%) 17 (43.6%)
Donor age (years) (range, average ± SD) 16 to 74 (54.5 ± 13.8)
Cold ischemic time (minutes, range, average ± SD) 240 to 775 (501.3 ± 121
Post-operative complication with bile duct
stricture/bile leakage
4 (10.3%)
LTx, liver transplantation; SD, standard deviation; HCC, hepatocellular carcinoma.graft from a deceased donor. The patients were divided
into two groups, those that received TAC from the first
day after transplantation (TAC group, n = 15) and those
that received CSA (CSA group, n = 24). Several clinical pa-
rameters at the time of transplantation were also analyzed,
including donor and recipient age, recipient gender, malig-
nancy and the cold ischemia time (CIT). Characteristics of
the patients in both groups are shown in Table 1. The
study was approved by the review board of the ethical
committee at Karolinska Institutet, Sweden.
Immunosuppression
During the study period, the selection of CSA or TAC in
patients with HCV cirrhosis was based on the operating
surgeons' own choice and no special criteria were used
(CSA; n = 14, TAC; n = 15). However, after November
2010, only CSA was used in these patients (CSA; n = 10).
All patients in the TAC group received a double-regime
immunosuppression protocol without induction therapy,
i.e., TAC + cortisone. The patients in the CSA group re-
ceived a triple immunosuppression regime without induc-
tion therapy, i.e., CSA +Azathioprine (AZA) + cortisone.
The initial dose was 0.1 mg/kg/day for the TAC group and
10 mg/kg/day for the CSA group, both divided in two
doses a day. The target trough level in the first three post-
operative months was 8 to 10 ng/ml for the TAC group
and 200 to 300 ng/ml for the CSA group. Beyond the
3 months, the target level was reduced to 4 to 6 ng/ml for
the TAC group and 150 to 200 ng/ml for the CSA group.
In the CSA group, CSA was converted to TAC treatment
in three patients before the 1-year follow-up scintigraphy
was performed. In the TAC group, TAC was converted to
everolimus in one patient at the time of the 1-year follow-
up. According to our protocol, the initial dosage of AZA
was 3 mg/kg at a maximum dose of 150 mg/day, reduced
to 1 to 2 mg/kg after the 3-month follow-up and subse-
quently withdrawn after the 1-year follow-up. However,
nine patients in the CSA group had the AZA removed
earlier than 1 year after LTx because of side effects, mainly






43 to 67 42 to 66 0.62
55.7 ± 6.8 56.8 ± 6.3
14/10 11/4 0.90
12 (50%) 5 (33.3%) 0.31
16 to 74 (53.3 ± 17.0) 43 to 64 (56.3 ± 6.4)
.9) 350 to 751 (513.3 ± 111.9) 240 to 775 (482.1 ± 138.3)
3 (12.5%) 1 (6.7%) 0.56
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3.0 months).Follow-up of the patients
All patients underwent a 3-month follow-up that in-
cluded hepatobiliary scintigraphy and blood biochemis-
try tests: s-bilirubin, alanine aminotransferase (ALAT),
aspartate aminotransferase (ASAT), alkaline phosphatase
(ALP), and gamma-glutamyl transpeptidase (GT). Hepa-
tobiliary scintigraphy and the same blood biochemistry
tests were repeated at the 1-year follow-up; in addition
creatinine and iohexol clearance and a liver biopsy were
performed at 1 year.Figure 1 Hepatobiliary scintigraphy. A 53-year old female patient who u
(case 2 in Table 4). Cyclosporin A was converted to tacrolimus treatment d
scintigraphy with 99mTc-Mebrofenin performed 3 months after LTx. Dynam
show a homogeneous accumulation of 99mTc-Mebrofenin in the transplant
injection. (b) A hepatobiliary scintigraphy with 99mTc-Mebrofenin in the sam
accumulation of 99mTc-Mebrofenin in the transplanted liver and excretion tHepatobiliary scintigraphy
Procedure
Hepatobiliary scintigraphy was performed on a large
field-of-view gamma camera (Diacam; Siemens, Munich,
Germany) at 3 months and 12 months post-operatively.
A dynamic acquisition was started directly after a bolus
injection of 200 MBq 99mTc mebrofenin, which is rapidly
taken up by hepatocytes from circulating blood and
extracted into the biliary tract without conjugation
(Figure 1a,b). Data were acquired at a rate of one frame
per 10 s over 30 min using a 256 × 256 matrix. The field
of view included the heart, the liver, and the upper abdo-
men. A 5-min anterior view was acquired 1 h after
injection.nderwent liver transplantation (LTx) due to hepatitis C virus cirrhosis
ue to peripheral neuropathy 5 months after LTx. (a) A hepatobiliary
ic study with recording time of 30 min in anterior projection. Images
ed liver and excretion to the small bowel at 15 to 20 min after
e patient performed 1 year after LTx. Visually homogeneous
o the small bowel in 10 to 15 min after injection.
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The HEF was calculated using a restricted matrix algo-
rithm deconvolution technique [17]. A region of interest
(ROI) was drawn over the left ventricle of the heart, ex-
cluding the aorta and scatter from the liver. A second
ROI was drawn over the entire liver parenchyma, ex-
cluding the main bile duct from the ROI in order to
eliminate the risk of overlapping of excreted radioactivity
from bile duct and the true radioactivity of the liver par-
enchyma (gallbladder was removed from the liver graft
during operation).
Time-activity curves were generated from these re-
gions, and the heart curve was used as the input func-
tion in the deconvolution analysis. The deconvoluted
liver curve thus represents a hypothetical true liver re-
sponse following a direct bolus injection into the hepatic
artery. An exponential curve was fitted by the least-
squares method to the deconvoluted liver curve. The
intercept of the fitted curve is proportional to the hep-
atocyte function, while the maximum of the deconvo-
luted liver curve represents the total input to the liver.
HEF is calculated as: HEF = intercept exponential-fit
liver response curve/max. data value liver response curve
(Figure 2a,b).
Liver biopsies
All liver biopsies were performed under the guidance of
ultrasound, and all were analyzed by one experienced
pathologist. The findings recorded were inflammation,
fibrosis, steatosis, and the histological evidence of HCV
recurrence. The grading system for the evaluation of the
degree of inflammation/fibrosis/steatosis is as follows: 0:
none, 1: light, 2: moderate, and 3: severe. HCV recur-
rence was diagnosed by the presence of focally intense
lymphocytic infiltrates in portal areas, focal infiltration
of a single interlobular bile duct without duct loss, a
variable degree of piecemeal necrosis, and the absence
of severe portal/hepatic venular endotheliitis [5].
Statistical analysis
The STATISTICA statistical program (Statsoft inc.,
Tulsa, OK, USA) was used for the statistical analysis in
this study. The chi-square test was performed for cat-
egorical variables and Student t test was performed for
continuous variables. A p values < 0.05 was considered
as statistically significant.
Results
Characteristics of CSA and TAC groups
In Table 1, the characteristics of both patient groups are
shown. There was no statistical difference of recipient,
donor and graft parameters, and post-operative compli-
cation between the CSA group and the TAC group.
Three patients in the CSA group and two patients in theTAC group received intravenous bolus steroid therapy
for biopsy-verified acute rejection within 3 months after
LTx. There was no statistical difference of the occur-
rence of acute rejection between the two groups.
Scintigraphic and biochemical parameters at a 3-month
follow-up
The time intervals between LTx and 3-month follow-up
hepatobiliary scintigraphy were 2.7 to 3.5, 3.1 ± 0.2 months
(range, average ± standard deviation (SD)). There was a
significant difference of the average of HEF values at the
3-month hepatobiliary scintigraphy; 11 to 90, 35.8 ± 21.2%
(range, average ± S.D.) in the CSA group and 46 to 100,
87.3 ± 14.8% in the TAC group (p < 0.0001). Average of
serum bilirubin was normal in both groups but signifi-
cantly higher in the CSA group. There was a significant
difference in the value of bilirubin between the two
groups, (18.1 ± 13.5 vs 8.9 ± 8.4 μmol/l, respectively; p =
0.02). ALAT, ASAT, ALP, and GT were similar between
the two groups (Table 2).
Scintigraphic and biochemical parameters 1-year after LTx
The time intervals between LTx and 1-year follow-up
hepatobiliary scintigraphy were 11.4 to 12.9, 12.1 ±
0.4 months (range, average ± SD). The average of HEF in
the CSA group was significantly lower at 1 year after
LTx than in patients treated with TAC (17 to 79, 44.7 ±
18.4% vs 37 to 100, 85.2 ± 23.6% (range, average ± SD);
p < 0001). The average HEF in CSA treated patients who
were on treatment with AZA at 1 year was 44.9 ± 19.4
compared to 53.3 ± 28.0 in patients who discontinued
AZA (p = 0.39). There was no statistical difference in the
liver and renal function by blood biochemistry evalu-
ation between the CSA and TAC groups (Table 3).
HEF of patients who converted from CSA to TAC
Table 4 shows the HEF and serum bilirubin values at
3 months and 1 year after LTx in three patients who con-
verted from CSA to TAC. Conversion was done between
3.7 to 6.3 months post-operatively. One patient (case 1)
had normal bilirubin at the time of the two follow-ups and
HEF increased from 27% to 90%. The second patient (case
2) who had slightly increased bilirubin at 3 months but a
normal value at 1 year had HEF increased from 42% to
100% after conversion. Hepatobiliary scintigraphy and
HEF of this case 3 months and 1 year after LTx are shown
in Figures 1 and 2. The third patient (case 3) who had
post-operative complication with bile duct stricture in-
creased HEF from 13% to 26% in spite of a significant in-
crease in serum bilirubin from 41 to 142 μmol/l.
HEF inpatients with post-surgical complications
Post-surgical complications were evaluated in the patients.
No re-operation was performed during the follow-up
Figure 2 Hepatic extraction fraction. A 53-year old female patient who underwent liver transplantation (LTx) due to hepatitis C virus cirrhosis
(case 2 in Table 4). Cyclosporin A was converted to tacrolimus treatment due to peripheral neuropathy 5 months after LTx. (a) Calculation of
hepatic extraction fraction (HEF) in the same patient at 3 months imaging. HEF is calculated by the ratio of the initial hepatocyte uptake divided
by the peak vascular uptake (42%). (b) Calculation of HEF in the same patient 1 year after LTx. HEF increased from 42% to 100%.
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and 1 in CSA converted to TAC at 6.3 months after LTx)
presented with bile duct stricture (n = 3) and bile leakage
(n = 1). Bile duct stricture and leakage was treated by
dilatation of the stricture and bile duct stent placement
with endoscopic retrograde cholangiopancreatography
(ERCP) and percutaneous transhepatic cholangio drainage
(PTCD). Table 5 shows the HEF and serum bilirubinvalues in these patients. Case 1 in the CSA group had nor-
malized bilirubin value at 1 year; however, the HEF de-
creased from 46% to 37%. Case 2 in the TAC group had
bile duct complications with high bilirubin values at both
3 months and 1 year after LTx even after the intervention
and had low HEF values; 14% and 17%, respectively. Case
4 in the CSA group, who had complication of bile leakage
after the removal of the T-tube at 1 month after LTx, had
Table 2 Results of scintigraphic and biochemical













HEF (%) 11 to 100 11 to 90 46 to 100 <0.0001
55.6 ± 31.6 35.8 ± 21.2 87.3 ± 14.8
Bilirubin (μmol/l) 2.0 to 59.0 5.0 to 59.0 2.0 to 38.0 0.02
Ref: <26 14.6 ± 12.6 18.1 ± 13.5 8.9 ± 8.4
ALAT (μkat/l) 0.1 to 1.6 0.1 to 1.6 0.2 to 1.0 0.57
Ref: <0.76 0.6 ± 0.3 0.6 ± 0.4 0.5 ± 0.2
ASAT (μkat/l) 0.2 to 2.5 0.2 to 2.5 0.2 to 1.2 0.33
Ref: <0.61 0.6 ± 0.4 0.7 ± 0.5 0.5 ± 0.2
ALP (μkat/l) 0.8 to 18.1 0.8 to 5.8 0.8 to 18.1 0.16
Ref: <1.9 2.1 ± 2.9 1.6 ± 1.2 3.0 ± 4.4
GT (μkat/l) 0.3 to 22.7 0.3 to 8.8 0.4 to 22.7 0.16
Ref: <1.3 2.8 ± 4.6 2.0 ± 2.3 4.1 ± 6.7
CSA, cyclosporine A; TAC, tacrolimus; ALAT, alanine aminotransferase; ASAT,
aspartate aminotransferase; ALP, alkaline phosphatase; GT,
gamma-glutamyl transpeptidase.
Table 4 Results of scintigraphic parameters in patients
who converted from CSA to TAC at 1-year control
Case 1 Case 2 Case 3
Time of converting
after LTx
3.7 months 5.0 months 6.3 months
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however, the HEF values were low; 29% and 41%,
respectively.
Liver biopsy at the 1-year follow-up
The results of the liver biopsy taken 1 year after LTx are
shown in Table 6. There was no significant difference inTable 3 Results of scintigraphic and biochemical













HEF (%) 17 to 100 17 to 79 37 to 100 <0.0001
62.8 ± 29.0 44.7 ± 18.4 85.2 ± 23.6
Bilirubin (μmol/l) 3.0 to 146.0 4.0 to 146.0 3.0 to 142.0 0.88
18.5 ± 30.4 17.8 ± 29.9 19.4 ± 32.0
ALAT (μkat/l) 0.2 to 3.9 0.2 to 3.0 0.2 to 3.9 0.13
1.1 ± 1.0 0.8 ± 0.7 1.3 ± 1.2
ASAT (μkat/l) 0.3 to 3.0 0.3 to 2.4 0.3 to 3.0 0.38
0.9 ± 0.7 0.8 ± 0.5 1.0 ± 0.9
ALP (μkat/l) 0.7 to 5.8 0.7 to 5.8 0.8 to 4.8 0.44
1.8 ± 1.0 1.9 ± 1.4 1.7 ± 1.0
GT (μkat/l) 0.2 to 26.2 0.4 to 8.1 0.2 to 26.2 0.12
3.2 ± 5.1 2.1 ± 2.3 4.6 ± 7.0
Creatinine, (μmol/l) 60.0 to 273.0 60 to 273.0 63 to 177.0 0.23
117.1 ± 44.6 124.9 ± 53.6 107.5 ± 28.7
Iohexol clearance,
(ml/min/1.7 m2)
6.4 to 91.0 18.0 to 78.0 6.4 to 91 0.33
51.3 ± 17.4 48.8 ± 16.0 54.4 ± 19.0degrees of fibrosis and steatosis between the CSA and
TAC groups; however, there was a significantly higher
degree of inflammation in the TAC group compared to
the CSA group (p = 0.005). The rate of the histopatho-
logically confirmed recurrence of hepatitis C was 57.1%
(12/21) in the CSA group and 50.0% (7/14) in the TAC
group (p = 0.68).
Discussion
The monitoring of graft function after LTx is a complex
procedure. Evaluation of graft function commonly con-
sists of liver blood biochemistry tests, liver biopsy, tran-
sient elastography, and hepatobiliary scintigraphy. Liver
transplant patients receive either CSA or TAC as the
main immunosuppressant. CSA has been shown to exert
some anti-HCV properties in vitro [18] and is still fre-
quently used in these patients. One animal study showed
a negative effect of CSA on the excretion of the tracer
99mTc-mebrofenin, thus possibly confusing the evalu-
ation of liver function when comparing patients treated
with CSA or TAC. The aim of this study was to evaluate
whether CSA impaired the result of hepatobiliary scin-
tigraphy using 99mTc-mebrofenin or not. For that pur-
pose, the results of HEF at 3 months and 1 year after
LTx were compared between the CSA and TAC groups.
In recent years, CSA has not been used as the initial
immunosuppressive drug at our institute, with the ex-
ception of HCV positive patients. To eliminate the re-
cipients' factor of primary disease that might affect graft
function, only patients who underwent LTx due to HCV
cirrhosis were evaluated in this study.
There was no difference in recipient and donor age,
recipient gender, malignancy rate, and CIT between the
CSA and TAC groups, which indicates that there is no
significant pre-LTx bias in the two patient groups. Neither
was there any difference in the occurrence of acute rejec-
tion, which indicates that there was no significant differ-
ence of the immunosuppressive potency between the two
groups.
Table 5 Results of scintigraphic parameters in patients who had bile duct complications
Case and
immunosuppression
Case 1 CSA Case 2 TAC Case 3 CSA to TAC Case 4 CSA
Complications, time of the
onset of treatment after LTx
Bile duct stricture, 4 months Bile duct stricture, 1.5 months Bile duct stricture,
5 months
Bile leakage after the
removal of T-tube,
1 month
Treatment Dilatation and bile duct stent
placement by ERCP, PTCD
Dilatation and bile duct stent
placement by ERCP, PTCD
Dilatation and bile duct
stent placement by ERCP
Bile duct stent placement
by ERCP, PTCD
3-month HEF (%) 46 14 13 29
Bilirubin, 3-month follow-up
(μmol/l)
38 59 41 16
1-year HEF (%) 37 17 26 41
Bilirubin, 1-year follow-up
(μmol/l)
8 146 142 18
LTx, liver transplantation; ERCP, endoscopic retrograde cholangiopancreatography; PTCD, percutaneous transhepatic cholangio drainage.
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significantly lower HEF values in the CSA group com-
pared to the TAC group. In addition, none of the CSA
patients had HEF of 100%, with the range being 11% to
90%, while in the TAC group, six patients (40%) acquired
100% of HEF (Tables 2 and 3).
In view of biochemical parameters, at 3-month follow-
up, there was no significant difference of ALAT, ASAT,
ALP, and GT between the two groups except bilirubin in
the TAC group that was significantly lower than in the
CSA group, although both were within normal range
(Table 2). This difference may to some extent explain
the difference in HEF between the two groups. However,
at the 1-year follow-up, there was no significant differ-
ence in liver function tests, including bilirubin and renal
function tests, between the two groups (Table 3). More-
over, the results of three patients converted from CSA to
TAC (Table 4) showed that HEF value increased without
any substantial difference of bilirubin in two cases (casesTable 6 Results of pathological parameters with CSA and







Low grade (0: none/1: light) 16 (2/14) 4 (1/5) 0.005
High grade (2: moderate/3: severe) 5 (6/0) 10 (8/2)
Fibrosis
Low grade (0: none/1: light) 12 (2/10) 6 (2/4) 0.40
High grade (2: moderate/3: severe) 9 (7/2) 8 (4/4)
Steatosis
Low grade (0: none/1: light) 13 (2/11) 11 (5/6) 0.30
High grade (2: moderate/3: severe) 8 (5/3) 3 (2/1)
Recurrence of hepatitis C
Presence/absence 12/9 7/7 0.68
Three patients who converted CSA to TAC were not included in this analysis.1 and 2) and in spite of a drastically increased bilirubin
in one case (case 3). The patients who developed post-
operative bile duct complication in the CSA group
remained with low HEF value in spite of a normalized
bilirubin level after treatment.
Although a ‘cholestatic’ effect of CSA, in contrast to
TAC, as indicated by a significantly higher level of serum
bilirubin at 3 months post-operatively should be consid-
ered, we interpret these overall data, supported by the
animal experimental study, as CSA causing an incorrect
diagnosis of hepatic dysfunction with hepatobiliary scin-
tigraphy through CSA interference not seen for TAC.
The evaluation of liver biopsy showed that the degree of
inflammation was higher in the TAC group than in the
CSA group. There was no difference in other histological
parameters; fibrosis, steatosis, and incidence of hepatitis C
recurrence. In spite of a higher degree of inflammation in
the TAC-treated patients, the HEF values were signifi-
cantly better than in the CSA group. The reason for the
higher degree of inflammation in the TAC group is not
clear. Moreover, the CSA-treated patients with normal
liver function tests and normal histology presented with
HEF values that only ranged from 17% to 79%.
Adenosine triphosphate (ATP)-binding cassette (ABC)
subfamilies are bile canalicular transporters. ABC sub-
family C member 2 (Abcc2) mediates the secretion of
amphiphilic glutathione, glucuronide, and sulfate conju-
gates into bile. Excretion of 99mTc-mebrofenin from he-
patocytes is mainly dependent on Abcc2. CSA is known
to be associated with the regulation of Abcc2-dependent
canalicular transport of bile salts and drugs [17]. Thus,
the administration of CSA can inhibit 99mTc-mebrofenin
excretion. An alternative mechanism is that low 99mTc-
mebrofenin excretion is due to an elevated serum biliru-
bin value [14]. If so, this could partly explain the HEF
difference at 3 months but not at 1 year after LTx. In-
flammation of hepatocytes normally inhibits the 99mTc-
mebrofenin excretion [19]. In our groups, this should
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sumably, such a possible effect was less important than
the negative effect on HEF by CSA.
To our knowledge, this study is the only investigation
in which a correlation between scintigraphy and several
clinical liver transplantation parameters, including liver
biopsy, that has been performed.
Conclusions
Our finding has significant clinical implications as it in-
dicates that the assessment of the liver graft function
may be misleading, due to low HEF values in CSA-
treated patients with otherwise good liver function. In
conclusion, hepatobiliary scintigraphy in patients under
CSA immunosuppression may show inadequately low
HEF values.
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